Skip to main content

Table 2 Observed responses in Box–Behnken design for development and optimization of NI formulations

From: Design and optimization of nano invasomal gel of Glibenclamide and Atenolol combination: in vitro and in vivo evaluation

  Factor 1 Factor 2 Factor 3 Response 1 Response 2 Response 3 Response 4
Run A:Phospholipid B:Ethanol C:D-Limonene EE of GLB EE of ATN Flux of GLB Flux of ATN
  % w/w % % % % μg/cm2/h μg/cm2/h
1 9 7.5 1 72.54 ± 0.83 69.54 ± 1.45 144.3 ± 0.98 355.8 ± 1.24
2 11.5 7.5 1.5 77.96 ± 0.92 75.54 ± 1.23 177.9 ± 1.34 436.7 ± 0.97
3 11.5 10 2 70.97 ± 1.54 67.76 ± 2.34 160.8 ± 1.43 380.2 ± 0.76
4 11.5 5 2 80.83 ± 2.23 78.43 ± 1.23 185.8 ± 1.67 442.6 ± 0.45
5 9 5 1.5 72.54 ± 1.43 70.54 ± 0.89 164.3 ± 2.45 365.8 ± 0.89
6 11.5 10 1 72.86 ± 2.54 71.56 ± 0.97 150.3 ± 1.68 405.6 ± 0.65
7 11.5 7.5 1.5 77.84±1.76 75.76 ± 1.45 180.8 ± 1.34 440.9 ± 1.34
8 11.5 5 1 78.97 ± 2.65 76.76 ± 1.34 190.8 ± 2.56 375.2 ± 2.98
9 9 10 1.5 65.95 ± 2.87 62.98 ± 1.45 120.3 ± 2.90 325.5 ± 2.67
10 14 10 1.5 90.93 ± 0.98 87.65 ± 2.18 215.8 ± 2.78 465.3 ± 1.34
11 11.5 7.5 1.5 78.33 ± 1.34 76.98 ± 1.47 185.4 ± 1.69 450.7 ± 1.56
12 9 7.5 2 74.94 ± 1.56 72.43 ± 1.45 147.9 ± 1.34 400.4 ± 1.67
13 14 5 1.5 97.62 ± 0.78 95.76 ± 1.67 249.3 ± 0.98 480.1 ± 2.45
14 11.5 7.5 1.5 70.97 ± 1.56 68.76 ± 0.67 175.8 ± 0.78 425.2 ± 2.09
15 14 7.5 2 94.93 ± 0.96 91.65 ± 0.57 240.8 ± 0.67 479.3 ± 1.76
16 11.5 7.5 1.5 77.84 ± 1.26 75.98 ± 1.36 186.9 ± 0.56 444.4 ± 2.76
17 14 7.5 1 95.94 ± 0.56 92.65 ± 1.35 239.8 ± 0.65 471.5 ± 1.45